Kufeld Neele, Weckbecker Klaus, Michalak Johannes, Häuser Winfried, Petzke Frank, Scherbaum Norbert, Specka Michael, Schmidt Alexandra, Piotrowski Alexandra, Kersting Christine, Just Johannes Maximilian
Chair of General Practice I and Interprofessional Care, Institute of General Practice and Primary Care, Faculty of Health, Witten/Herdecke University, Witten, Germany.
Department of Psychology and Psychotherapy, Witten/Herdecke University, Witten, Germany.
J Pain Res. 2024 Mar 5;17:873-885. doi: 10.2147/JPR.S445153. eCollection 2024.
Substance use disorders (SUD) are a challenging comorbidity in patients with chronic non-cancer pain (CNCP) as they complicate diagnosis and therapy, especially when opioids are part of the therapeutic regimen. A definite diagnosis of opioid use disorder (OUD) in patients with CNCP on long-term opioid therapy (LTOT) is a prerequisite for effective and targeted therapy but may be complicated as some criteria of OUD might be attributed to the desire of the patient to relieve the pain. For instance, the desire to increase the dose can be based on both a SUD as well as inadequate pain therapy. Many scientific studies use standardized questions. Therefore, potential misunderstandings due to possible diagnostic overlaps often cannot be clarified.
14 qualitative guided interviews were conducted and analyzed (Kuckartz content analysis), with the intention to verify if patient's initial response to simple questions based on the wording of the DSM-5, as commonly used in research and practice, were consistent with the results of a more in-depth inquiry.
The results suggest that without in-depth investigation, there is a particular risk of false-positive assessment of the DSM-5 criteria for OUD when opioids are prescribed, especially when the questions are considered independently of chronic pain. The risk of a false-negative assessment has also been shown in isolated cases.
Only after asking for and describing specific situations it was possible to determine whether the patient's positive or negative answers were based on a misunderstanding of the question. To avoid misdiagnosis, staff conducting DSM-5 interviews should be trained in pain-specific follow-up questions that may help to uncover diagnostic confounding.
物质使用障碍(SUD)是慢性非癌性疼痛(CNCP)患者中具有挑战性的合并症,因为它们会使诊断和治疗复杂化,尤其是当阿片类药物作为治疗方案的一部分时。对接受长期阿片类药物治疗(LTOT)的CNCP患者进行阿片类药物使用障碍(OUD)的明确诊断是有效和针对性治疗的先决条件,但可能会很复杂,因为OUD的一些标准可能归因于患者缓解疼痛的愿望。例如,增加剂量的愿望可能既基于物质使用障碍,也基于疼痛治疗不足。许多科学研究使用标准化问题。因此,由于可能的诊断重叠而导致的潜在误解往往无法澄清。
进行并分析了14次定性引导访谈(库卡尔茨内容分析),目的是验证患者对研究和实践中常用的基于《精神疾病诊断与统计手册》第5版(DSM-5)措辞的简单问题的初始回答是否与更深入询问的结果一致。
结果表明,在未进行深入调查的情况下,开具阿片类药物时,对DSM-5中OUD标准存在假阳性评估的特别风险尤其当这些问题被独立于慢性疼痛考虑时。在个别案例中也显示出假阴性评估的风险。
只有在询问并描述具体情况后,才有可能确定患者的肯定或否定回答是否基于对问题的误解。为避免误诊,进行DSM-5访谈的工作人员应接受有关疼痛特异性后续问题的培训,这些问题可能有助于发现诊断混淆。